IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation

US11292788B2 · kind B2 · utility

Assignee

• IMMUNIC AG · DE

Inventors

• Jakob Felding · Copenhagen, DK
• Hella KOHLHOF · Munich, DE
• Manfred GRÖPPEL · Erlangen, DE
• Rolf Andreas Muhler · Munich, DE
• Daniel VITT · Germering, DE
• Carine Chevrier · Munich, DE
• Mirko Zaja · Birkenfeld, DE
• Stefan Tasler · Hanerau-Hademarschen, DE

Key dates

• Filing date: Sep 6, 2018
• Grant date: Apr 5, 2022
• Expiry date: Oct 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation.